التفاصيل البيبلوغرافية
| العنوان: |
Combination of a Silicon Containing Component and a Hormone |
| Document Number: |
20110311633 |
| تاريخ النشر: |
December 22, 2011 |
| Appl. No: |
11/885669 |
| Application Filed: |
March 03, 2006 |
| مستخلص: |
The invention relates to the use of a silicon-containing material to reduce the amount of hormone required in a method of hormone treatment to achieve a desired response, particularly in hormone replacement therapy (HRT) and especially in the maintenance of post-menopausal bone health and the management or treatment of osteoporosis, and to pharmaceutical compositions for use in such a method. |
| Inventors: |
Canham, Leigh Trevor (Worcestershire, GB); Powell, Jonathan Joseph (Cambridge, GB); Jugdaohsingh, Ravin (London, GB) |
| Claim: |
1. Use of a silicon containing component to reduce the amount of hormone required to be administered per day to a human or animal subject in order to achieve the desired therapeutic effect in a method of hormone treatment. |
| Claim: |
2. Use according to claim 1 wherein the hormone has oestrogen pathway interacting activity or bone influencing activity. |
| Claim: |
3. Use according to claim 1 wherein the hormone is a sex hormone or a thyroid hormone. |
| Claim: |
4. Use according to claim 1 wherein the hormone has oestrogenic activity. |
| Claim: |
5. Use according to claim 1 in hormone replacement therapy |
| Claim: |
6. Use according to claim 1 in treating or preventing osteoporosis. |
| Claim: |
7. Use according to claim 1 wherein the silicon containing component is selected from silicic acid, porous silicon or silicon particles with a surface area exceeding 25 m2/g. |
| Claim: |
8. Use of a hormone and a silicon containing component in the manufacture of a medicament for the treatment or prevention of a condition in a human or other animal subject in which enhancing the level of hormone is indicated to be beneficial, wherein the amount of hormone administered per day is lower than the normal effective dose of hormone per day in the treatment in the absence of the silicon containing component. |
| Claim: |
9. Use according to claim 8 wherein the hormone is an oestrogen hormone. |
| Claim: |
10. Use according to claim 9 in the manufacture of a medicament for the treatment or prevention of osteoporosis. |
| Claim: |
11. Use according to claim 9 wherein the oestrogen is selected from estrone, estropipate, equilin, estradiol, estradiol valerate, ethinyl estradiol, quinestrol, estriol, dienestrol, mestranol, conjugated oestrogen or a mixture thereof. |
| Claim: |
12. Use according to claim 8 wherein the silicon containing component is selected from silicic acid, porous silicon or silicon particles with a surface area exceeding 25 m2/g. |
| Claim: |
13. Use according to claim 9 wherein the oestrogen is administered in an amount of from 10% to 90% of the normal effective dose of oestrogen per day in the treatment in the absence of the silicon containing component. |
| Claim: |
14. Use according to claim 9 wherein the oestrogen is administered in an amount of from 10% to 70% of the normal effective dose of oestrogen per day in the treatment in the absence of the silicon containing component. |
| Claim: |
15. Method for treating or preventing a condition in which enhancing the level of hormone is indicated to be beneficial in a human or other animal subject comprising administering to the subject a silicon containing component and administering to the subject a hormone in an amount per day which is lower than the normal effective dose of hormone per day in the treatment in the absence of the silicon containing component. |
| Claim: |
16. Method according to claim 15 wherein the hormone has oestrogenic activity. |
| Claim: |
17. Method according to claim 15 for treating or preventing osteoporosis. |
| Claim: |
18. Method according to claim 15 wherein the hormone is selected from estrone, estropipate, equilin, estradiol, estradiol valerate, ethinyl estradiol, quinestrol, estriol, dienestrol, mestranol, conjugated oestrogen or a mixture thereof. |
| Claim: |
19. Method according to claim 15 wherein the silicon containing component is selected from silicic acid, porous silicon or silicon particles with a surface area exceeding 25 m2/g. |
| Claim: |
20. Method according to claim 16 wherein the oestrogen is administered in an amount of from 10% to 90% of the normal effective dose of oestrogen per day in the treatment in the absence of the silicon containing component. |
| Claim: |
21. Method according to claim 20 wherein the oestrogen is administered in an amount of from 10% to 70% of the normal effective dose of oestrogen per day in the treatment in the absence of the silicon containing component. |
| Claim: |
22. A pharmaceutical composition for co-administration comprising a silicon containing component and an oestrogen, wherein the oestrogen is present in an amount which is lower than the normal effective dose of oestrogen per day in the treatment in the absence of the silicon containing component. |
| Claim: |
23. Use of porous silicon and oestrogen in the manufacture of a medicament for the treatment or prevention of a condition in which enhancing the level of oestrogen is indicated to be beneficial in a human or other animal subject. |
| Claim: |
24. Method of treating or preventing a condition in which enhancing the level of oestrogen is indicated to be beneficial in a human or other animal subject comprising administering to the subject porous silicon and an oestrogen. |
| Claim: |
25. A pharmaceutical composition comprising porous silicon and an oestrogen. |
| Claim: |
26. Use of a composition according to claim 25 in therapy in a human or other animal subject. |
| Current U.S. Class: |
424/489 |
| Current International Class: |
61; 61; 61 |
| رقم الانضمام: |
edspap.20110311633 |
| قاعدة البيانات: |
USPTO Patent Applications |
